Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of ...
Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results